Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of Arrowhead Pharmaceuticals Inc. common stock. The group holds 6,384,903 shares, representing 4.53% of the outstanding class of Arrowhead’s common stock.
Within this position, Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over 6,384,903 shares, with no shared voting or dispositive power reported. The stake is held across Vanguard investment companies and other managed accounts for which Vanguard entities exercise voting and/or dispositive authority. No other individual investor’s interest in the reported securities exceeds 5% of the class.
BlackRock, Inc. filed an amended Schedule 13G reporting a significant ownership position in Arrowhead Pharmaceuticals Inc. common stock. BlackRock reports beneficial ownership of 14,232,545 shares, representing 10.1% of Arrowhead’s outstanding common stock.
BlackRock has sole voting power over 13,849,022 shares and sole dispositive power over 14,232,545 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no individual client holds more than five percent of Arrowhead’s outstanding common shares.
Arrowhead Pharmaceuticals director Matthew Gregory Cohen received an equity award. On the grant dated 06/15/2026, he acquired 11,882 shares of Common Stock underlying restricted stock units at no cash cost. These units vest over three years, and following the grant he directly holds 11,882 shares.
Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 indicating no current ownership of the company’s Common Stock. The filing lists a holding entry in Common Stock with total shares following the report shown as 0. This is a baseline disclosure of his position as a newly reported insider, rather than a buy or sell transaction.
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors appointed Dr. Matt Cohen, M.D., M.B.A., as a director, effective June 12, 2026. Dr. Cohen brings more than 25 years of healthcare investing and portfolio management experience, including senior roles at JP Morgan Asset Management and Vida Ventures.
He will receive standard non-employee director compensation plus a sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years. The company states there are no family relationships or appointment-related arrangements with other persons, and Dr. Cohen will enter into Arrowhead’s standard indemnity agreement.
Arrowhead Pharmaceuticals, Inc. officer Daniel Apel reported a proposed sale of 13,095 common shares, with an aggregate market value of $934,206.16 and an approximate sale date of April 22, 2026. The amendment adds a Rule 10b5-1 plan adoption date of September 16, 2025. Merrill Lynch is named as broker.
ARWR insider notice: Hongbo Lu filed a Form 144/A disclosing proposed sale of 2,970 shares of common stock, with an aggregate amount shown as $228,298.95. The filing lists 03/15/2026 and an execution/filing date of 05/12/2026, and identifies the sale reason as compensation.
Arrowhead Pharmaceuticals, Inc. (ARWR) officer James Hamilton amended a Form 144 notice covering the proposed sale of 10,000 common shares, with an aggregate market value of $749,997.60 and an approximate sale date of April 23, 2026. The notice identifies December 2, 2025, as the date the Rule 10b5-1 plan was adopted. It also reports that Hamilton sold 10,000 common shares on March 5, 2026, for gross proceeds of $641,870.05 during the preceding three months.
Arrowhead Pharmaceuticals director Hongbo Lu reported an open-market sale of company stock. On the reported date, Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at a price of $76.88 per share in a single transaction.
The filing states this sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares on a scheduled basis. After this transaction, Lu directly owned 52,012 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying previously granted restricted stock units, some of which are still subject to vesting conditions.